巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Kintara Therapeutics

KTRA
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Kintara Therapeutics - 延遲價格・最後更新於 24/01 12:15
最高位
0.376
最低位
0.333
開市價
--
前收市價
0.400
成交量(千)
15.67
成交額(百萬)
0.05
買入
--
賣出
--
每手股數
--
市值(百萬)
17.96
市盈率
--
息率
--
差價
--
52週高低
3.350 - 0.333
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Kintara Therapeutics
證券代碼
KTRA.US
所屬板塊
Biotechnology
公司業務
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
發行量
43174989
公司總部
12707 High Bluff Drive, Suite 200
公司網址
https://www.kintara.com
公司電郵
ir@delmarpharma.com
公司電話
+1 858 350-4364
暫無內容

關於

Kintara Therapeutics(KTRA.US)所屬的行業板塊為Biotechnology。
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.
詳細公司背景可參考: https://www.kintara.com